Samsung Biologics Delays PolyPeptide Acquisition to Dec. 31, 2026
Samsung Biologics postponed its planned PolyPeptide acquisition to Dec. 31, 2026, from Nov. 30, 2026, in an Oct. 16 correction. The planned KRW 2.71 trillion acquisition covers 33,016,411 shares, representing a 100% stake, to strengthen its peptide contract development and manufacturing business. Disclaimer: This news